

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award  
*Kim Allyson Margolin, MD*
  - Highlights of the Day II including Partners in Progress Award  
*Douglas W. Blayney, MD*
  - Partners in Progress Award Recipient  
*Ellen V. Sigal, PhD*
  - Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
  - Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
  - Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
  - Discussion: Myeloma  
*Jean L. Harousseau, MD*
  - Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*
- 

**Session Title:** #16: Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- Overview of adjuvant clinical trials in stage II colon cancer - results, challenges, and confusion  
*Al Bowen Benson, III, MD*

- Prognostic and predictive molecular biomarkers in stage II colon cancer - current evidence and future perspective

*Sabine Tejpar, MD, PhD*

- Biomarker-driven treatment decisions in stage II colon cancer - making sense of what we know

*Neal J. Meropol, MD*

---

**Session Title:** #20: Cancer Survivors: A Challenge to Health Care Systems Worldwide

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- ASCO's Efforts to Promote Survivorship Care

*Douglas W. Blayney, MD*

- Follow-up and other health care needs of cancer survivors: how are different health care systems meeting the challenge?

*Eva Grunfeld, MD, D.Phil.*

- Life-threatening long-term effects after cancer: Who needs what follow-up?

*Sophie D. Fossa, MD*

- Challenges and opportunities in developing a cancer survivorship program in the context of current trends in oncology care

*Lawrence N. Shulman, MD*

- The Needs of Cancer Survivors

*Eliezer Robinson, MD*

---

**Session Title:** #29: Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 8:00 AM - 9:15 AM

- Tailoring Adjuvant Therapy for HER2 Negative Breast Cancer

*Harold J. Burstein, MD, PhD*

- Small HER2-positive Tumors: When to Add Anti-HER2 Therapy?

*Ana M. Gonzalez-Angulo, MD, MSc*

- Is It Ok Not to Give Chemotherapy in Node-Positive Breast Cancer?

*Anthony Howell, MD*

---

**Session Title:** #41: Disparities in Cancer Care

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S404

**Time:** 8:00 AM - 9:15 AM

- Complex etiologies and strategies for reducing disparities in cancer care

*Beverly Moy, MD, MPH*

- Evolving U.S. population demographics and implications for disparities in cancer care

*Lisa A. Newman, MD, MPH*

- Cancer care in different contexts: Domestic and international perspectives

*Michael Silbermann, DMD, PhD*

---

**Session Title:** #54: Health Disparities in Lung Cancer: Race, Sex, and Genes

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 8:00 AM - 9:15 AM

- Molecular Epidemiology of Lung Cancer: Ancestry Matters

*Alex A. Adjei, MD, PhD*

- Molecular Genetic Variations Between Human Populations

*Patrick C. Ma, MD, MSc*

- Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

*Nithya Ramnath, MD*

**Session Title:** #58: Impact of Health Literacy on Health Care, Decision Making and Consent

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 8:00 AM - 9:15 AM

- Impact of limited health literacy; assessing literacy and overcoming barriers to limited literacy in delivering health care

*Terry C Davis, PhD*

- overcoming literacy issues in obtaining informed consent

*Cathy A. Coyne, PhD*

- Decision making in breast and prostate cancer

*Angela Fagerlin, PhD*

---

**Session Title:** #87: Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 8:00 AM - 9:15 AM

- Prognostic markers in CLL, do they matter?

*Sami N. Malek, MD*

- CLL in the elderly. How should it be treated?

*Clive Zent, MD*

- Evolving therapies for CLL

*Susan Mary O'Brien, MD*

---

**Session Title:** #97: The Biology and Treatment of Wilms Tumor

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 8:00 AM - 9:15 AM

- Wilms Tumor: Unsettled questions and controversies

*Jeffrey Dome, MD*

- Gene Expression Arrays: What have they taught us about Wilms tumor?

*Elizabeth Perlman, MD*

---

**Session Title:** #105: Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 8:00 AM - 9:15 AM

- Management options for early stage seminoma and non-seminoma

*Christian K. Kollmannsberger, MD*

- Is RPLND still relevant?

*David Peter Wood, MD*

- Toxicity and survivorship in testicular cancer survivors. Should it modify what I do?

*George J. Bosl, MD*

---

**Session Title:** #106: Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 8:00 AM - 9:15 AM

- Target genes of chimeric transcription factors in pediatric sarcomas: a source of potential therapeutic targets

*Marc Ladanyi, MD*

- Targeting protein products of sarcoma specific translocations with small molecules

*Jeffrey Toretsky, MD*

- IGF1R targeting of translocation-associated sarcomas

*Lee J. Helman, MD*

**Session Title:** #114: Contract Negotiation for Your First Job

**Session Type:** Meet the Professor Session

**Date:** Monday, June 7

**Location:** E451b

**Time:** 8:00 AM - 9:15 AM

- Contract Negotiation for Your First Job

*Jamie H. Von Roenn, MD*

---

**Session Title:** #139: The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 8:00 AM - 9:15 AM

- Diagnosis and Management of the Renal Mass

*Steven Campbell, MD, PhD*

- Management of Non-clear Cell Histology

*Przemyslaw Twardowski, MD*

- Optimal Management of Toxicities Related to Targeted Agents

*Tim Eisen, PhD, FRCP*

---

**Session Title:** #180: Genitourinary (Prostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450a

**Time:** 8:00 AM - 12:00 PM

- Genitourinary (Prostate) Cancer

*Andrea Lynne Harzstark, MD*

- Genitourinary (Prostate) Cancer

*Daniel W Lin*

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

*Shreya K. Shah*

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

*Aseem Anand*

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

*Eleni Efstathiou*

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

*Tomasz M. Beer, MD, FACP*

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

*Emmanuel S. Antonarakis, MD*

- Discussion: Biomarkers of response in prostate cancer

*Johann Sebastian De Bono, MD, PhD*

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel- $\tau$ ; trials in metastatic castration-resistant prostate cancer.

*Celestia S. Higano, MD*

8 #4551-Persistence of immunotherapy survival effects of sipuleucel- $\tau$ ; and relationship to postrandomization docetaxel use in phase III studies.

*Daniel Peter Petrylak*

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel- $\tau$ ; , an autologous active cellular immunotherapy for the treatment of prostate cancer.

*Frances P Stewart*

- Discussion: Can we predict who will respond to immunotherapy?

*Robert Dreicer, MD*

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

*Paul L. De Souza*

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

*Daniel Keizman*

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

*Mark T. Fleming*

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

*Mark N. Stein*

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

*Mary-Ellen Taplin, MD*

- Discussion: Novel therapies and response predictors for CRPC

*Celestia S. Higano, MD*

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

*Evan Y. Yu, MD*

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

*Karynsa Cetin*

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

*Shireen Marzouk*

- Discussion: The impact of ADT on bone and brain

*Matthew Raymond Smith, MD, PhD*

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*David G Bostwick*

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*Otis W. Brawley*

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

*Douglas Reding*

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

*Silke Gillissen*

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

*E. David Crawford*

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

*Joel B. Nelson, MD*

---

**Session Title:** #186: Lung Cancer - Metastatic

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450b

**Time:** 8:00 AM - 12:00 PM

- Lung Cancer - Metastatic

*Shirish M. Gadgeel, MD*

- Lung Cancer - Metastatic

*Taofeek Kunle Owonikoko, MD*

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

*Andreas Claudius Hoffmann*

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

*David R. Gandara*

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

*Rafael Rosell*

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

*Bruce E. Johnson, MD*

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

*Lecia Sequist, MD*

- Discussion: Biomarkers

*Michael J. Kelley, MD*

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

*Rabab Mohamed Gaafar*

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

*Lampros Vamvakas*

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

*Geoffrey Raymond Oxnard*

10 #7521^~A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

*Chih-Hsin Yang*

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

*Suresh S. Ramalingam, MD*

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

*Michael J. Boyer*

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

*Natasha B. Leigh*

- Discussion: New approaches in EGFR targeted therapy

*Karen L. Reckamp, MD, MS*

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

*Jin Soo Lee*

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

*Fairooz F. Kabbinavar*

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

*Baohui Han*

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

*George R Blumenschein, Jr, MD*

- Discussion: Anti-angiogenic agents

*Silvia Novello, MD, PhD*

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

*Hiroshige Yoshioka*

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

*Thomas James Lynch*

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

*Primo Lara, MD*

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) &plusmn; bevacizumab (B) &plusmn; dulanermin (D) in non-small cell lung cancer (NSCLC).

*Fiona Hellen Blackhall*

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

*Christos Stelios Karapetis*

- Discussion: New agents

*Suresh S. Ramalingam, MD*

**Session Title:** #188: Melanoma/Skin Cancers

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** S403

**Time:** 8:00 AM - 12:00 PM

- Melanoma/Skin Cancers

*Gregory A. Daniels, MD, PhD*

- Melanoma/Skin Cancers

*Ravi K. Amaravadi, MD*

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

*Jeffrey Alan Sosman, MD*

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

*Christiane A. Voit*

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

*Nabil Wasif*

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

*Michael B. Atkins, MD*

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

*Vernon K Sondak, MD*

- Discussion

*Julie R. Lange, MD*

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

*Lore Decoster, MD*

7 #8519^--A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

*Richard D. Carvajal*

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

*Reinhard Dummer*

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

*Roger Mouawad*

- Discussion

*David F. McDermott, MD*

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

*Donald P. Lawrence*

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

*Ahmad A. Tarhini*

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

*Omid Hamid*

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

*Axel Hauschild*

- Discussion

*Henry B. Koon, MD*

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

*Jun Guo, MD, PhD*

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

*Lynn G. Feun*

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

*Grant A. McArthur, PhD*

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

*Naomi B. Haas*

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

*Wen-Jen Hwu*

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

*Alain Patrick Algazi*

- Discussion

*Anna C. Pavlick, MD*

---

**Session Title:** #197: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

1A #2539-A phase I study of CD40 agonist monoclonal antibody (CP-870, 893) with gemcitabine in pancreatic cancer.

*Gregory Lawrence Beatty*

1B #2540-Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

*David S. Hong, MD*

1C #2541-A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

*Daniel D. Von Hoff, MD*

1D #2542-Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines.

*Kevin S. Clive*

1E #2543-PET imaging of [11C]docetaxel uptake and tumor perfusion in lung cancer.

*Astrid A. van der Veldt*

1F #2544-Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.

*Michael Morse*

1G #2545-Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI organ dysfunction working group (ODWG) study (NCI #8057).

*Merrill J. Egorin, MD*

1H #2546-A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol.

*Jorge G. Ignacio*

2A #2547-Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.

*Laura Quan Man Chow, MD, FRCPC*

2B #2548-Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

*Martin David Forster*

2C #2549-New approach for assessment of potential ethnic differences in parallel phase I/II studies in the United States and Asia.

*Toshihiko Doi*

2D #2550-Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

*Ravi Amrit Madan*

2E #2551-The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study.

*Marion Gabriele Ott*

2F #2552-A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

*Udai Banerji*

2G #2553-Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

*Huiping Xu*

2H #2554-Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors.

*Michael B. Jameson*

3A #2555-CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.

*Arvin Yang, MD, PhD*

3B #2556-ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

*John Sarantopoulos*

3C #2557-Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors.

*Johanna Wilmink*

3D #2558-A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential.

*Bert L. Lum, PharmD*

3E #2559-NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors.

*Patrick J. Mansky, MD*

3F #2560-A phase I study of sonopizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

*Michael S. Gordon*

3G #2561-Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors.

*Christophe Massard*

3H #2562-A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma).

*A. Dasari*

4A #2563-A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors.

*Jana Portnow*

4B #2564-Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors.

*Alice C. Fan*

4C #2565-Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations.

*Guy T. Clifton*

4D #2566-Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial.

*Andres J. Ferreri*

4E #2567-Effect of TGF- $\beta$ 1 expressed on tumor-derived exosomes on survival and function of regulatory T cells.

*Hideya Onishi, DrPH, MD*

4F #2568-Factors of interindividual hematopoietic toxicity of carboplatin.

*Etienne Chatelut*

4G #2569-Effect of prophylactic administration of recombinant human thrombopoietin on chemotherapy-induced severe thrombocytopenia in patients with advanced non-small cell lung cancer: A prospective self-control clinic study.

*Shun Lu*

4H #2570-A phase I study of ARRY-520 in solid tumors.

*Priscila H. B. Goncalves*

5A #2571-A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD).

*Stephen Shibata*

5B #2572-Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.

*Wiete Kromdijk*

5C #2573-Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.

*Walter M. Fiedler*

5D #2574-Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression.

*Diane I. Healey*

5E #2575-Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN).

*Carter Van Waes*

5F #2576-Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.

*Glen J. Weiss*

5G #2577-Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin.

*Yoshinori Makino*

5H #2578-Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade.

*Lawrence Fong*

6A #2579-Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.

*Christian H.H Ottensmeier*

6B #2580-Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.

*S. Gail Eckhardt, MD*

6C #2581-Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy.

*Beatrice Nardone*

6D #2582-Eribulin mesylate pharmacokinetics in patients with hepatic impairment.

*Petronella Witteveen*

6E #2583-PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

*Filip Janku*

6F #2584-Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies.

*Austin J. Combest*

6G #2585-Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.

*Ling-Zhi Wang*

6H #2586-Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC).

*Thandiwe C. Gray*

7A #2587-Correlation of immune responses with survival in a randomized phase II study investigating multi-peptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

*Harpreet Singh*

7B #2588-Improving patient selection for oncology phase I trials: Predictors of 90-day mortality and overall survival.

*Nicole Grace Chau, MD, FRCPC*

7C #2589-Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.

*Umang Swami, MBBS*

7D #2590-Phase I/II study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma.

*David A. Reardon*

7E #2591-A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.

*Ezra E. W. Cohen, MD, FRCPC*

7F #2592-A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-small cell lung cancer (NSCLC).

*Aradeep Chatterjee, MD*

7G #2593-Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors.

*Marine Gilabert*

7H #2594-Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.

*Martin Zweifel*

8A #2595-Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies.

*Ernesto Bustinza-Linares*

8B #2596-Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

*Weiwei Tan*

8C #2597-Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.

*Naifa Busaidy*

8D #2598-Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

*Mark Kozloff*

8E #2599-A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

*Lulama Rhoda Molife*

8F #2600-Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy.

*Dae Won Kim*

8G #2601-A comparison of the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs.

*Joseph A. Grillo, PharmD*

8H #2602-A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors.

*Amir Mortazavi*

9A #2603-Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN).

*John Charles Morris*

9B #2604-Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience.

*Jennifer J. Wheler*

9C #2605-A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

*Shivaani Kummar*

9D #2606-Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.

*Gianluigi Lunardi*

9E #2607-Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle.

*Maja De Jonge*

9F #2608-Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results.

*Bijal Dinesh Shah*

9G #2609-Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.

*Margaret A. Marshall*

9H #2610-Phase I trial of dasatinib (D) and lapatinib (L).

*Charles Erlichman*

10A #2611-Trabectedin (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.

*Helmut Oettle*

10B #2612-Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.

*Margaret von Mehren, MD*

10C #2613-A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

*Richard D. Baird, MBBS, MRCP*

**Session Title:** #198: Developmental Therapeutics - Experimental Therapeutics**Session Type:** General Poster Session**Date:** Monday, June 7**Location:** S Hall A2**Time:** 8:00 AM - 12:00 PM

10D #3034-Phase I study of PF-03446962, a fully human mab against ALK 1, a TGF $\beta$ ; receptor involved in tumor angiogenesis.

*Laura Williams Goff*

10E #3035-Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

*Toshio Shimizu*

10F #3036-French, multicentric, prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients.

*Nathalie Lassau*

10G #3037-Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer.

*Michael B. Bass*

10H #3038-Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

*Francisco Robert*

11A #3039-Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

*Herbert Hurwitz*

11B #3040-Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies.

*Surena F. Matin*

11F #3041-Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer.

*Gary K. Schwartz, MD*

11G #3042-Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

*Jared Gollob*

11H #3043-Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.

12B #3045-Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

*Marlies HG Langenberg*

12F #3046-A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors.

*Smitha S. Krishnamurthi*

12G #3047-Phase I clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.

*A. Fasolo*

12H #3048-Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC).

*Ben Suttle*

13A #3049-Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study.

*Susanta K. Sarkar*

13B #3050-Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI.

*Robert Jeraj*

13C #3051-Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T).

*Ingrid Desar*

13D #3052-Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI) induced macrocytosis.

*Paul Hamberg*

13E #3053-Extended linifanib therapy in patients with advanced solid tumors in a phase I trial.

*Boon C. Goh*

13F #3054-A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation.

*Geoffrey Chong*

13G #3055-Phase II trial of dose-escalated sorafenib in advanced solid tumors.

*Thomas John Semrad*

13H #3056-Association of VEGF feedback production in bevacizumab therapy with systemic response.

*Patrick Starlinger*

14A #3057-A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

*E. Angevin*

14B #3058-A phase I dose-escalation study of IMGN388 in patients with solid tumors.

*Dana Shelton Thompson*

14C #3059-A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors.

*Anthony B. El-Khoueiry, MD*

14D #3060-Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

*Dennis J. Slamon, MD, PhD*

14E #3061-Final analysis of a phase I single dose escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

*Thierry Gil*

14F #3062-Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

*Nicoletta Brega*

14G #3063-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.

*Rastislav Bahleda*

14H #3064-A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

*Adil Daud*

15A #3065-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.

*Sara Cresta*

15B #3066-Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

*Peter J. Rosen*

15C #3067-A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

*Suzanne Leijen*

15D #3068-Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL).

*Carmelo Carlo-Stella*

15E #3069-Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors.

*Geoffrey Shapiro*

15F #3070-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

*Cristian Moldovan*

15G #3071-First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

*Eve T. Rodler*

15H #3072-Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors.

*Thierry Lesimple*

16A #3073-Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC).

*Kirk Salvatore Culotta*

16B #3074-Application of multinomial (MN) phase II designs in trials of targeted agents.

*Rahima Jamal*

16C #3075-Novel strategy to identify drugs that delay relapse.

*Marcia Hall*

16D #3076-Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1 $\alpha$ .

*Raoul Tibes*

16E #3077-Phase I trial of OGX-427, a 2'-methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.

*Sebastien J. Hotte*

16F #3078-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

*Anne M. Traynor, MD*

16G #3079-A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.

*Saoirse Dolly*

16H #3080-A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN).

*Eleni M Karapanagiotou*

17A #3081-Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

*Suzanne Fields Jones*

17B #3082-A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle.

*Sunil Sharma*

17C #3083-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

*James M. Cleary*

17D #3084-Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study.

*Robert Dreicer, MD*

17E #3085-A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.

*Phioanh Leia Nghiemphu*

17F #3086-Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603).

*Myrna Rachel Rosenfeld, MD, PhD*

17G #3087-First-in-human study evaluating safety and pharmacokinetics of endoxifen, a potent estrogen-receptor antagonist for breast cancer.

*Ateeq Ahmad*

17H #3088-A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer.

*Wael A. Harb*

18A #3089-Final results from a phase I, dose escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

*Antonio Jimeno*

18B #3090-Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression.

*Rachel Anne Goodwin*

18C #3091-Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.

*Anitha S Nallari*

18D #3092-Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program.

*Kristine Rose*

18E #3093-Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan.

*Darren O. Davis*

18F #3094-Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU).

*Michael Roger Harrison*

18G #3095-Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors.

*Xiaoning Wang*

18H #3096-Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer.

*Akihito Kubo*

19A #3097-Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.

*Vered Stearns, MD*

19B #3098-Pharmacogenetic factors predicting the need for a higher dose of imatinib.

*Heinz-Josef Klumpen*

19C #3099-DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine.

*Maarten J. Deenen, PharmD*

19D #3100-Relationship of *HLA-DQA1\*0201* and lapatinib-induced hepatotoxicity in women with advanced breast cancer.

*Colin F Spraggs*

19E #3101-The contribution of *UGT1A* and *ABCB1* to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer.

*Eric Levesque*

19F #3102-Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.

*Sant P. Chawla*

19G #3103-Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors.

*Karen Kelly*

19H #3104-Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

*Jayesh Desai*

20A #3105-A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.

*David C. Smith*

20B #3106-Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (Study 265-101).

*Michel A. Drouin*

20C #3107-Evaluation of serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib.

*Yi Pei*

20D #3108-A phase I study of oral administration of MGCD265 in patients with advanced malignancies (Study 265-102).

*Elisabeth I. Heath*

**Session Title:** #221: Paths for Clinical Development of PI3K Inhibition

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 8:00 AM - 9:30 AM

- Paths for Clinical Development of PI3K Inhibition

*Pasi A. Janne, MD, PhD*

- Paths for Clinical Development of PI3K Inhibition

*A. Dimitrios Colevas, MD*

- Discussion

*Neal Rosen, MD, PhD*

- #3003-A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

*Jose Baselga, MD*

- #3004-A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

*Gerald Edelman*

- #3005-First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

*Howard Burris*

- Discussion: Next steps in clinical development of PI3K inhibitors?

*Carlos L. Arteaga, MD*

---

**Session Title:** #273: Trials in Progress Poster Session

**Session Type:** Trials in Progress Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

20E #TPS100-Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.

*Jasjit C. Sachdev*

20F #TPS101-Feasibility of an exercise program for aromatase inhibitor-related arthralgia (AIRA) in breast cancer survivors.

*Jessica Katz*

20G #TPS102-A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer.

*P. Kelly Marcom*

20H #TPS103-TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.

*Erica L. Mayer, MD*

21A #TPS104-ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast.

*Gunter Von Minckwitz*

21B #TPS105-A multicenter randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study).

*Norikazu Masuda*

21C #TPS106^-WGS PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.

*Oleg Gluz*

21D #TPS107-A phase II clinical trial of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group (FB-6/VEG110264).

*Priya Rastogi*

21E #TPS108-A randomized, pharmacologic intervention study evaluating the effect of the angiotensin II-receptor blocker candesartan versus placebo to prevent trastuzumab-associated cardiotoxicity in women with early breast cancer.

*Renske Altena*

21F #TPS109-Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer.

*Frankie Ann Holmes*

21G #TPS110-Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.

*William M. Sikov*

21H #TPS111-A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008).

*Roisin M. Connolly*

22A #TPS112-SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with previously untreated primary breast cancer (BC).

22B #TPS113-MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas.

*Matthew Stephen Block*

22C #TPS114-Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial.

*Thorsten Kühn, Prof., Dr.*

22D #TPS115-A new resource to accelerate translational breast cancer research: The Love/Avon Army of Women.

*Susan M. Love*

22E #TPS116-LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial.

*David A. Cameron, MD*

22F #TPS117-Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall.

*Nicholas Borys*

22G #TPS118-A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071.

*Kelly Hunt*

22H #TPS119-A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC).

*Ingrid A. Mayer*

23A #TPS120-A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.

*Henry Leonidas Gomez*

23B #TPS121-Suppression of bone turnover following treatment with zoledronic acid in patients with metastatic breast cancer: Duration of effect—The SuBDuE study.

*Christine E. Simmons*

23C #TPS122-Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in *FGFR1*-amplified and nonamplified HER2-negative metastatic breast cancer.

*Fabrice Andre*

23D #TPS123-Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients.

*Joachim Bischoff*

23E #TPS124-Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC).

*Patrick Glyn Morris*

23F #TPS125-Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC).

*John D. Hainsworth*

23G #TPS126-Metronomic chemotherapy with cyclophosphamide and celecoxib in breast cancer patients progressing after standard chemotherapy: Phase I/II trial.

*Viviana R Rozados*

23H #TPS127-Randomized phase II study of metronomic chemotherapy (MC) plus aromatase inhibitor (AI) versus MC alone in postmenopausal hormone receptor-positive, metastatic breast cancer (MBC), with correlative circulating endothelial cell (CEC), circulating endothelial progenitor cell (CEP), VEGF, and VEGFR levels.

*Nan Soon Wong*

24A #TPS128-A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC).

*Denise Aysel Yardley*

24B #TPS129-N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer.

*Paul Haluska*

24C #TPS130-Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC).

*Lajos Pusztai*

24D #TPS131-Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC).

*Lori J. Goldstein*

24E #TPS132-TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).

*Nancy U. Lin, MD*

24F #TPS133-Three parallel randomized phase II trials of dasatinib plus hormone therapy (HT) in advanced ER+ breast cancer (ER+ ABC).

*Lewis C. Strauss, MD*

24G #TPS134-A phase II comparative study of metformin plus first-line chemotherapy (CT) versus CT alone in HER2-negative, insulin-resistant (IR), nondiabetic metastatic breast cancer (MBC).

*Alessandra Gennari*

24H #TPS135-A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).

*Wolfgang Janni*

25A #TPS136-A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients.

*Daigo Yamamoto*

25B #TPS137-Comparison of zoledronic acid retention in bone of multiple myeloma and breast cancer patients: Consequences for efficacy?

*Kent Søre*

25F #TPS138-Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to breast cancer chest wall recurrences or skin metastases.

*Sylvia Adams*

25G #TPS139-Utilization of 5HTT-gene polymorphism as a prognostic indicator in cancer.

*Noha Mahmoud Nasr Awad, MD, PhD*

25H #TPS140-Fish oil, green tea, and prostate cancer prevention.

*Jackilen Shannon*

26A #TPS141-A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer.

*Marie Wood, MD*

26B #TPS142-Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer.

*Katherine D. Crew*

26F #TPS143-Sulforaphane supplementation in women newly diagnosed with DCIS: A biomarker study.

*Jackilen Shannon*

26G #TPS144-Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients.

*Antonio Marcilio Padula Omuro*

26H #TPS145-Phase II trial of chemotherapy with temozolomide in combination with topotecan for central nervous system (CNS) metastases of solid tumors.

*Pamela Z. New*

27A #TPS146-Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies.

*John C. Grecula*

27B #TPS147-A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas.

*Ramin Altaha, MD*

27C #TPS148-Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases.

*David Peereboom, MD*

27E #TPS150-A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma.

*Prakash Chinnaiyan*

27F #TPS151-Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study.

*Louis B. Nabors*

27G #TPS152-Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC).

*Roger Stupp, MD*

27H #TPS153-An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging and molecular markers during bevacizumab/irinotecan therapy for recurrent malignant glioma.

*Markus Hutterer*

28A #TPS154-Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma.

*Michael Weller*

28B #TPS155-Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS).

*Klaus Pietzner*

28C #TPS156-Catumaxomab observational study to investigate efficacy and safety profile in clinical practice.

*Volker Kunzmann*

28D #TPS157-Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung cancer.

*Jay M Lee*

28E #TPS158-New approaches in dendritic cell vaccination design and efficacy tests for patients with advanced ovarian cancer: Prospects for a phase I clinical study.

*Marianne Imhof*

28F #TPS159-An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors.

*Muralidhar Beeram*

28G #TPS160-Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel.

*Emiliano Calvo*

28H #TPS161-Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patients on ART.

*John F. Deeken*

29A #TPS162-Use of a human ribonuclease variant, QBI-139, for the treatment of cancer.

*Laura E. Strong*

29B #TPS163-Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.

*Geoffrey Kim*

29C #TPS164-A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden.

*Paul N. Mainwaring*

30A #TPS165-Attempt to improve the safety of development studies with a new design for phase I combination trials of targeted therapies: The PARASOL trial.

*Sylvie Negrier*

30B #TPS166-Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer.

*Brian Addis Costello*

30C #TPS167-Selective inhibition of proliferating endothelial cells: A phase I/IIa study of the novel organoarsenical compound GSAO in patients with advanced solid tumors.

*Gireesh Kumaran*

31A #TPS168-Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors.

*Weiqiang Zhao*

31B #TPS169-A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.

*Crystal Shereen Denlinger*

31C #TPS170-SORAVE trial: Phase I sorafenib and everolimus in solid tumors.

*Lucia Nogova*

32A #TPS171-A randomized, open-label phase IIb study of maintenance therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.

*Heidi J. Gray*

32B #TPS172-Multiple tumor associated peptide vaccination as consolidation treatment in women affected by breast and ovarian cancer.

*Marianna Nuti*

32C #TPS173-A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer.

*Uhi Toh*

33A #TPS174-A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission.

*Catherine S. Magid Diefenbach*

33B #TPS175-Endogenous heat-shock protein vaccines for metastatic melanoma.

*James M. Heun*

33C #TPS176-Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy.

*Shaveta Mehta*

34A #TPS177-A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.

*April F. Eichler*

34B #TPS178^ -Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE).

*Riccardo Lencioni*

34C #TPS179-Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.

*Niels G Borgstein*

35A #TPS180-A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors.

*Amita Patnaik*

35B #TPS181-Combination of vorinostat with whole-brain radiotherapy in the treatment of brain metastases.

*Yaacov Richard Lawrence*

35C #TPS182-Correlation between FLT-PET and Ki-67 change in breast cancer during neoadjuvant chemotherapy

*Samuel C. Blackman, MD, PhD*

35D #TPS183-APR-246, a new class anticancer compound in phase I/IIa clinical trials.

*Charlotta Liljebris, BSc, PhD*

35E #TPS184-Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study.

*Susan Wroblewski*

35F #TPS185-An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

*Gedske Daugaard*

35G #TPS186-A randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328, an anti-IL-6) in patients with multicentric Castleman's disease.

*Jessica Vermeulen*

35H #TPS187-A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM).

*Leonardo Trani*

36A #TPS188-An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors.

*Michael S. Gordon*

36B #TPS189-PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type *KRAS*.

*Lee Schwartzberg*

36C #TPS190-Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type *KRAS* colorectal cancer with metastases confined to liver.

*Samuel A. Jacobs*

36D #TPS191-A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT).

*Irene Yu-Shing Chong*

36E #TPS192-FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer.

*Richard G. Gray*

36G #TPS194-Phase I/II personalized therapy trial for metastatic colorectal cancer using functional pathway mapping: Stratification to imatinib therapy.

*Mariaelena Pierobon*

36H #TPS195-SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type *KRAS* tumors.

*Allen Lee Cohn*

37A #TPS196-Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study.

*Carlos Fernandez-Martos*

37B #TPS197-Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver.

*Ravi Murthy*

37C #TPS198-Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial.

*Francis Levi*

37D #TPS199-The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.

*Ramon Salazar*

37E #TPS200-Perioperative chemotherapy plus bevacizumab with early salvage therapy based on PET response in patients with locally advanced resectable gastric/GEJ cancer.

*Elizabeth Catherine Smyth*

37F #TPS201-Phase I study of sunitinib with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) for advanced gastroesophageal cancers.

*Nikhil I. Khushalani*

37H #TPS203-Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma.

*Jia Li*

38A #TPS204-A phase II trial of combined treatment of endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study JCOG0508.

*Tomohiro Tsuchida*

38B #TPS205-Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071).

*Arnaud Roth*

38C #TPS206-Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC).

*Ajlan Atasoy*

38D #TPS207-Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence.

*Feng Bi*

38E #TPS208-DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors.

*Bertram Wiedenmann, MD, PhD*

38F #TPS209-A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060).

*Manish Shah*

38G #TPS210-Gefitinib in the adjuvant treatment of hepatocellular carcinoma: A pilot study by the Singapore hepatocellular carcinoma consortium.

*Gilberto Lopes*

38H #TPS211-Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT).

*Abby B. Siegel*

39A #TPS212-A phase I trial of escalating doses of the anti-IGF-1R monoclonal antibody (mAb) cixutumumab (IMC-A12) and sorafenib for treatment of advanced hepatocellular carcinoma (HCC).

*Robert O'Donnell*

39B #TPS213-A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC).

*Robin Katie Kelley*

39F #TPS214-Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study.

*Weijing Sun*

39G #TPS215-ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC).

*Ivan Borbath*

39H #TPS216-Dose-escalating study of yttrium 90 microspheres with capecitabine for intrahepatic cholangiocarcinoma or metastatic disease to the liver.

*Ryan M Hickey*

40A #TPS217-Combined biological treatment and chemotherapy for patients with inoperable cholangiocarcinoma.

*Lars Henrik Jensen*

40B #TPS218-ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers.

*Juan W. Valle, MD*

40F #TPS219-The antiproliferative effect of pasireotide LAR alone and in combination with everolimus (RAD001) in patients with progressive medullary thyroid cancer (MTC): A single-center, open-label, phase II, proof-of-concept study.

*Antongiulio Faggiano, Bsc, MD*

40G #TPS220-Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma.

*Lowell Brian Anthony*

40H #TPS221-A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC).

*Irene Yu-Shing Chong*

41A #TPS222-A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.

*Somnath Mukherjee*

41B #TPS223-SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer.

*Philip Agop Philip*

41C #TPS224-APRICOt-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients.

*George P. Keogh, MD*

41D #TPS225-CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial.

*Jens Stieler*

41E #TPS226-A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations.

*Samuel H. Whiting*

41F #TPS227-Novel early stopping rule uses early progression rather than lack of response as rapid assessment for futility.

*Yu-Ning Wong*

41G #TPS228-A randomized phase II study of a novel antigen-presenting cell-targeted hCG- $\beta$ ; vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer.

*Deborah Ann Bradley, MD*

41H #TPS229-Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.

*Matthew I. Milowsky, MD*

42A #TPS230-Pilot study of external hyperthermia and intravesical mitomycin-C to treat recurrent bladder cancer after failed standard therapy.

*Zeljko Vujaskovic*

42B #TPS231-A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma.

*Srikala S. Sridhar*

42C #TPS232-First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC).

*Jennifer J. Knox, MD, FRCP*

42D #TPS233-Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC).

*B. Tannir*

42E #TPS234-Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma.

*Silvia Caglio*

42F #TPS235-Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC).

*Eric Jonasch, MD*

42G #TPS236-Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001.

*Lauren Christine Harshman*

42H #TPS237-A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC).

*Bernard J. Escudier*

43A #TPS238-Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma.

*Alain Ravaud*

43B #TPS239-Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab.

*Ajjai Shivaram Alva*

43C #TPS240-A phase II trial of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced and metastatic carcinoma of the penis (CRUK/09/001).

*Amit K Bahl*

43D #TPS241-A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC).

*Russell Zelig Szmulewitz*

43E #TPS242-Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC).

*Dana E. Rathkopf, MD*

43F #TPS243-Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in treatment of intermediate- and high-risk localized prostate cancer.

*Sumit Talwar, MD*

43G #TPS244-Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.

*Geoffrey Gibney*

43H #TPS245-First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer.

*Philip Kantoff*

44A #TPS246-A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

*Urban Emmenegger*

44B #TPS247-Phase I dose-escalation study of docetaxel/prednisone and fractionated <sup>177</sup>Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC).

*Himisha Beltran*

44C #TPS248-A randomized phase II trial of <sup>177</sup>Lu radiolabeled monoclonal antibody J591 (<sup>177</sup>Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy.

*Scott T. Tagawa*

44D #TPS249-Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.

*Andrew J. Armstrong, MD, ScM*

44E #TPS250-Phase I/II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development.

*Mark Garzotto*

44F #TPS251-Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial.

*James Paul Dean*

44G #TPS252-Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.

*Israel Zigelboim*

44H #TPS253-Phase I/II trial of reovirus serotype 3&ndash;Dearing strain in patients with recurrent ovarian cancer.

*David E. Cohn, MD*

45A #TPS254-Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

*Karina Dahl Steffensen*

45B #TPS255-A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.

*Lorraine Elit*

45C #TPS256-Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer.

*William P. McGuire, MD*

45D #TPS257-A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer.

*John D. Hainsworth*

45E #TPS258-Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer.

*Geoffrey Kim*

45F #TPS259-A phase II trial of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).

*Koji Matsumoto*

45G #TPS260-Enrolling a rare patient population: Establishing proof of concept for FP-1039, an FGF "trap," in endometrial cancer patients with the S252W FGFR2 mutation.

*Harold N. Keer*

45H #TPS261-A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix.

*Sunesh Kumar Jain*

46A #TPS262-A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).

*Robert L. Ferris*

46B #TPS263-Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone.

*Marcia S. Brose*

46C #TPS264-Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).

*Athanasios Panayotis Kotsakis*

46D #TPS265- Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial).

*Andreas Dietz*

46E #TPS266-A phase I/II study of erlotinib in combination with chemoradiation in patients with surgically resected locally advanced squamous head and neck cancer (HNSCC).

*Fernando Arias de la Vega*

46F #TPS267-VortigERN: Variation of radiotherapy target volume definition, dose to organs at risk (OAR), and clinical target volumes using anatomic (CT) versus combined anatomic and molecular imaging (PET-CT): Intensity-modulated radiotherapy delivered using a tomotherapy hi art machine.

*Sanjoy Chatterjee*

46G #TPS268-Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib (GORTEC-GETTEC CARISSA trial): Implications for sensitivity to gefitinib.

*Juliette Thariat*

46H #TPS269-Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome-proliferator activated receptor gamma receptors expression.

*Luiz Otavio Pita De Oliveira, MD*

47A #TPS270-Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial.

*Weidong Lu*

47B #TPS271-Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck.

*Athanasios Panayotis Kotsakis*

47C #TPS272-A pilot study comparing a patient-centered symptom-reporting follow-up program to standard care in patients who have completed the acute phase of treatment for early breast cancer.

*Michelle E. Melisko*

47D #TPS273-Telephone-based health coaching for cognitive, affective, and quality-of-life improvement in patient-caregiver cancer survivorship: A mixed-methods educational intervention.

*David Robert Close*

47E #TPS274-Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

*Amylou C. Dueck*

47F #TPS275-CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.

*Jonathan E. Kolitz*

47G #TPS276-A phase IIb study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML).

*Jürgen Krauter*

47H #TPS277-The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia.

*Jorge E. Cortes*

48A #TPS278-A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia.

*Ante Sven Lundberg*

48B #TPS279-A multicenter dose-finding randomized controlled phase IIb study of the aptamer AS1411 in patients with primary refractory or relapsed AML.

*Robert K. Stuart*

48C #TPS280-An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients.

*Daniel Aaron Pollyea*

48D #TPS281-Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib.

*Julie A. Rosenberg*

48E #TPS282-A phase II study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

*Oliver G. Ottmann*

48F #TPS283-A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis.

*Daniel J. DeAngelo, MD, PhD*

48G #TPS284-Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.

*Wenzhao Zhong*

48H #TPS285-A multi-institutional feasibility study of induction pemetrexed (Pem) plus cisplatin (Cis) followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (RT) for malignant pleural mesothelioma (MPM): Japan Mesothelioma Research Center (JMRC) 001001 trial.

*Fumihiko Tanaka*

49A #TPS286-A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer.

*Roy H. Decker*

49B #TPS287-Trial of poor performance status patients (ToPPS): A randomized phase II trial of pemetrexed versus pemetrexed/bevacizumab versus pemetrexed/carboplatin/bevacizumab in patients with stage IIIb/IV non-small cell lung cancer and ECOG performance status 2.

*David R. Spigel*

49C #TPS288-Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter phase II study.

*Arjun Pennathur*

49D #TPS289-Peripheral non-small cell lung cancer treated in stereotactic conditions: A prospective medico-economic French study.

*Line Claude*

49E #TPS290-Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology.

*Ralph Zinner*

49F #TPS291-Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies.

*Erin Marie Bertino*

49G #TPS292-Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors.

*Elaine Tat Lam*

49H #TPS293-Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC.

*Keith M Kerr*

50A #TPS294-Phase II trial evaluating addition of fulvestrant to erlotinib in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who are stable on erlotinib and exhibit immunohistochemical (IHC) or PCR positivity for estrogen or progesterone receptor (PR).

*Lyudmila Bazhenova*

50B #TPS295-Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC).

*Edward Garon*

50C #TPS296-Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ;) monoclonal antibody (IMC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC).

*David E. Gerber*

50D #TPS297-A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of  $\beta_2$ -cell lymphomas.

*Herve Tilly*

50E #TPS298-ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL).

*Anas Younes*

50F #TPS299-An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL).

50G #TPS300-A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients.

*Frederick Lansigan*

50H #TPS301-Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies.

*Stephen Edward Forbes Spurgeon*

51A #TPS302-A phase II trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic lymphoma.

*Claudius Rudin*

51B #TPS303-A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab.

*Panteli Theocharous*

51C #TPS304-RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL).

*Eliza Anne Hawkes*

51D #TPS305-Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma.

*Jason R. Westin, MD*

51E #TPS306-A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma.

*Lawrence D. Kaplan, MD*

51F #TPS307-Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts).

*Nikhil C. Munshi*

51G #TPS308-PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).

*Melissa Alsina*

51H #TPS309-A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma.

*Janice M. Mehnert*

52A #TPS310-Treatment of melanoma with wild-type p53 (wtp53) and detectable S100B using pentamidine: A phase II trial with correlative biomarker endpoints.

*Janice M. Mehnert*

52B #TPS311-Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study.

*Laura Ridolfi*

52C #TPS312-A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).

*Kevin Kalinsky*

52D #TPS313-LPS-activated dendritic cell vaccine in combination with immunomodulatory dose of cytoxan in patients with stage IV melanoma: Phase I/IIa clinical trial.

*Anna Karolina Palucka*

52E #TPS314-An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM).

*Evan Hersh*

52F #TPS315-Randomized phase II study of gabapentin alone versus gabapentin plus tramadol for the management of oxaliplatin-induced peripheral neuropathy.

*Hyun-Jeong Shim*

52G #TPS316-Evaluation of a Web-based cognitive rehabilitation program for cancer survivors with self-reported cognitive impairment.

*Victoria Jane Bray*

52H #TPS317-ICORG 07-11: A phase II trial evaluating the efficacy of a radiobiological based re-irradiation strategy for patients with malignant spinal cord compression.

*Pierre Guillaume Thirion, MD*

53A #TPS318-The effect of dexamethasone on symptom burden in patients with advanced cancer.

*Sriram Yennurajalingam*

53B #TPS319-A randomized placebo-controlled trial of melatonin for poor appetite in advanced cancer patients.

*Egidio Del Fabbro*

53F #TPS320-A randomized, controlled trial of parenteral hydration in patients with advanced cancer.

*Eduardo Bruera, MD*

53G #TPS321-A randomized, double-blind, controlled trial of methylphenidate for fatigue in patients with advanced cancer.

*Eduardo Bruera, MD*

53H #TPS322-Phase II randomized study of compound Chinese herbal extract LC09 for external treatment of hand-foot syndrome induced by anticancer therapy.

*Liqun Jia, MD, PhD*

54A #TPS323-Feasibility of a comprehensive lifestyle modification program during and for one year after completing cancer treatment in breast and prostate cancer patients in a large urban health center.

*Eleanor M. Walker*

54B #TPS324-A randomized comparison of oral methadone as a "first-switch" opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems.

*Ahmed F. Elsayem*

54F #TPS325-Design of an ongoing randomized study on the long-term safety and efficacy of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant with chemotherapy (ACC).

*Pedro Gascon*

54G #TPS326-A phase III randomized, double-blind, placebo-controlled study of pegfilgrastim in first-line colorectal cancer patients receiving bevacizumab and either FOLFOX or FOLFIRI.

*Tamas Pinter*

54H #TPS327-A phase I study of clofarabine and liposomal daunorubicin in childhood and adolescent acute myeloid leukemia.

*Nicola Jane Graham, MSc*

55A #TPS328-Randomized phase II study of two cross-over sequences comprising vinorelbine/cyclophosphamide and temozolomide/etoposide in outpatient setting for relapsed or refractory solid tumors in children and young adults.

*Mari Saito*

55B #TPS329-A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma.

*Giselle Linda Saulnier Sholler*

55C #TPS330-A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).

*Julia C Chisholm*

55D #TPS331-Viscum album fermentatum Pini versus oral etoposide as adjuvant treatment in osteosarcoma patients after second relapse.

*Alessandra Longhi*

55E #TPS332^-Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

*Paolo Giovanni Casali*

55F #TPS333-Phase I and II trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with soft tissue sarcoma of the extremity.

*Abimbola Olusanya*

55G #TPS334-An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide.

*Sant P. Chawla*

55H #TPS335-Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

*Kelly Shea Perlewitz*

56A #TPS336-Phase 0 microdose trial to identify chemoresistance in lung and bladder cancer.

*Paul T Henderson*

56B #TPS337-Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer.

*Karen L. Reckamp, MD, MS*

56C #TPS338-MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors.

*Madeleine Hewish*

56D #TPS339-Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer.

*Hugo Ford*

56E #TPS340-Molecular prognostic and predictive markers in gynecologic cancers: The translational 1 (T-1) study of the Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) group.

*Anna Maria Mosconi*

56F #TPS341-DCIS neoadjuvant therapy: Targeting the autophagy pathway in malignant precursor cells.

*Virginia A. Espina*

56G #TPS342-Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial.

*Amir Goldkorn*

56H #TPS343-Autophagy as a therapeutic target in cancer treatment.

*Vassiliki Karantza*

---

**Session Title:** #62: Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 9:30 AM - 10:45 AM

- Review of standard and emerging therapies for localized and advanced urothelial cancer

*David I. Quinn, PhD, FRACP, MBBS*

- Personalizing therapy for urothelial cancer: clinical and molecular biomarkers

*Jonathan E. Rosenberg, MD*

- How to overcome barriers to the adoption of neoadjuvant therapy for locally advanced urothelial cancer

*Ralph deVere White, PhD*

---

**Session Title:** #144: Breast Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 9:30 AM - 12:30 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy

*Rita Nanda, MD*

- Breast Cancer - Local-Regional and Adjuvant Therapy

*Seema Ahsan Khan, MD, FACS, MPH*

- #CRA504-ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer.

*Richard Cote*

- #LBA505-Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients

*David N. Krag*

- #CRA506-ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node.

*Armando E. Giuliano*

- #507-Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.

*Kevin S. Hughes, MD, FACS*

- Discussion

*William C. Wood, MD*

- #508-Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial.

*Stephen K. L. Chia, MD*

- #509-Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.

*Gong Tang, PhD*

- #510-Pharmacogenetics of tamoxifen in relation to disease-free survival in a dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

*Vincent O. Dezentje*

- Discussion

*Angelo Di Leo, MD, PhD*

- #511-Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.

*Kathy S. Albain*

- #512-Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.

*Georg Pfeiler, MD*

- Discussion

*Pamela Jean Goodwin, MD*

**Session Title:** #156: Health Services Research

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S404

**Time:** 9:30 AM - 12:30 PM

- Health Services Research

*Sarah T. Hawley, MD, PhD*

- Health Services Research

*Elena B. Elkin, PhD*

- #6000-Changes over time in quality of psychosocial care: Results from the Quality Oncology Practice Initiative (QOPI).

*Paul B. Jacobsen*

- #6001-Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials.

*Steven K Cheng*

- #6002-Assessment of performance measures for patients with the myelodysplastic syndrome (MDS) in the United States.

*Gregory Alan Abel*

- Discussion: Implementing performance measures to improve patient care

*Steven J. Katz, MD*

- #6003-Comparison of SEER registry data to patient self-report.

*Reshma Jagsi*

- #6004-State-wide application of breast and colon cancer quality measures (QMs) using linked claims and registry data.

*Stephen B. Edge, MD*

- #6005-Comorbidity severity and long-term mortality in men with early-stage prostate cancer.

*Timothy J. Daskivich*

- #6006-Development of a performance status prediction model for use in administrative data analyses.

*Amy J. Davidoff*

- #6007-Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer.

*Aileen B. Chen*

- #6008-Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC)

**Session Title:** #157: Leukemia, Myelodysplasia, and Transplantation

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 9:30 AM - 12:30 PM

- Leukemia, Myelodysplasia, and Transplantation

*Jessica K. Altman, MD*

- Leukemia, Myelodysplasia, and Transplantation

*William G. Blum, MD*

- #LBA6500-Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.

*Hagop Kantarjian*

- #6501-Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

*Richard A. Larson*

- #6502-Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).

*Jorge E. Cortes*

- Discussion: Chronic Phase CML- Beyond Imatinib?

*Michael J. Mauro, MD*

- #6503-Time-dependent decision analysis: Stable disease in azacitidine (AZA) treated patients (pts) with higher-risk MDS.

*Steven Gore*

- #6504-A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS).

*Elias Jabbour*

- #6505-Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-.

*Dietger Niederwieser*

- Discussion: High risk MDS and AML in the elderly. Are we making progress?

*Jeffrey E. Lancet, MD*

- #6506-Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

*Deborah A. Thomas*

- #6507-Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

*Susan Mary O'Brien, MD*

- #6508-A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia.

*Xavier Badoux*

**Session Title:** #165: Pediatric Oncology II

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 9:30 AM - 12:30 PM

- Pediatric Oncology II

*Tara O. Henderson, MD, MPH*

- Pediatric Oncology II

*Gregory T. Armstrong, MD, MSCE*

- #9512-Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study.

*Javier G. Blanco*

- #9513-Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial.

*Steven Lipshultz*

- #9514-Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.

*Amanda M. Termuhlen*

- Discussion: Cardiac status in survivors of pediatric cancer

*Melissa M. Hudson, MD*

- #9515-Childhood cancer: Do females experience more acute toxicities than males? A Report from the Children's Oncology Group

*Kathleen Ann Meeske*

- #9516-MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.

*Gregory A Yanik*

- #9517-Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study.

*Susan Lerner Cohn, MD*

- #9518-Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.

*Wendy B. London, PhD*

- Discussion: Prognostic Variables in Neuroblastoma

*Andrew Pearson, MD, FRCP*

- #9519-Multiple subsequent neoplasms in the childhood cancer survivor study (CCSS) cohort.

*Gregory T. Armstrong, MD, MSCE*

- #9520-Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

*Tara O. Henderson, MD, MPH*

- Discussion

*Flora E. Van Leeuwen, PhD*

---

**Session Title:** #50: Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 9:45 AM - 11:00 AM

- Family and caregiver needs over the course of the cancer

*Barbara Given, PhD, RN, FAAN*

- Partner-based interventions to enhance coping and pain management, and reduce distress in individuals with cancer

*Francis J. Keefe, PhD*

- Capitalizing on the Mother-Daughter bond to promote primary and tertiary prevention. Diet and Exercise Interventions to Promote Weight Loss and Improve Diet and Exercise Behaviors among Overweight Women with Breast Cancer and their Daughters

*Wendy Demark-Wahnefried, MD*

**Session Title:** #77: Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 9:45 AM - 11:00 AM

- (Neo)adjuvant chemotherapy in the management of localized esophagogastric carcinoma.

*Peter C. Enzinger, MD*

- Neoadjuvant chemoradiation in the management of localized esophagogastric carcinoma.

*Mohan Suntharalingam, MD*

- Implications for surgery following chemotherapy or chemoradiation.

*Cliff P. Connery, MD*

**Session Title:** #93: Seminal Advances in Lung Cancer Research 2010: Translational and Clinical

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 9:45 AM - 11:00 AM

- Translational Advances in Lung Cancer

*Ravi Salgia, MD, PhD*

- Clinical Advances in Lung Cancer

*Ramaswamy Govindan, MD*

- Perspectives on Recent Advances in Lung Cancer

*Jeffrey Crawford, MD*

**Session Title:** #102: Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the NCI's Clinical Trials and Translational Research Advisory Committee

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 9:45 AM - 11:30 AM

- Recommendations by the IOM on Reinvigorating Cooperative Group Clinical Trials

*John Mendelsohn, MD*

- The Role of Cooperative Groups in Comparative Effectiveness Research

*Richard L. Schilsky, MD*

---

**Session Title:** #113: Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor

**Session Type:** Meet the Professor Session

**Date:** Monday, June 7

**Location:** E451b

**Time:** 9:45 AM - 11:00 AM

- Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor

*Evanthia Galanis, MD*

---

**Session Title:** #141: Treatment of Barrett's Esophagus to Prevent Esophageal Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Esophageal resection for high-grade dysplasia and superficial cancer

*Hiran C. Fernando, MD, MBBS*

- Multimodality approaches for endoscopic ablation of Barrett's esophagus

*Kenneth K Wang, MD*

- Risk stratification, chemoprevention and early detection in Barrett's esophagus

*Brian J. Reid, MD, PhD*

**Session Title:** #224: Novel Therapies and Approaches for Management of Gynecologic Cancers

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 9:45 AM - 11:15 AM

- Novel Therapies and Approaches for Management of Gynecologic Cancers

*Ronald J. Buckanovich, MD*

- Novel Therapies and Approaches for Management of Gynecologic Cancers

*Robert L. Coleman, MD*

- #5000-Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

*Beth Y. Karlan*

- Discussion: Anti-angiogenic options in Ovarian Cancer. (Please take note of other PK abstract with AMG 386. Abst 47850)

*George Coukos, MD, PhD*

- #5001-Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.

*Allan J. White, MD*

- Discussion: Targeting the folate receptor in ovarian cancer. (Please also note functional folate receptor imaging abstract 44469)

*Alan Hilary Calvert, MD*

- #5002-Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.

*Hal W. Hirte*

- Discussion: Mechanisms of resistance in ovarian cancer.

*Hani Gabra, PhD, FRCP*

**Session Title:** #226: Promising Targeted Therapies for Head and Neck Cancer

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E354a

**Time:** 9:45 AM - 11:15 AM

- #5500-Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.

*Sandra Schmitz, MD*

- Discussion

*Bonnie S. Glisson, MD*

- #5501-BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

*Tanguy Y. Seiwert, MD*

- #5502-Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.

*Razelle Kurzrock, MD*

- Discussion

*Manisha H. Shah, MD*

---

**Session Title:** #266: American Cancer Society Award and Lecture

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 9:45 AM - 11:00 AM

- American Cancer Society Award and Lecture

*Joseph V. Simone, MD*

---

**Session Title:** #255: Melanoma/Skin Cancers

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 11:00 AM - 12:00 PM

- Melanoma/Skin Cancers

*Gregory A. Daniels, MD, PhD*

- Melanoma/Skin Cancers

*Ravi K. Amaravadi, MD*

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

*Jeffrey Alan Sosman, MD*

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

*Christiane A. Voit*

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

*Nabil Wasif*

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

*Michael B. Atkins, MD*

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

*Vernon K Sondak, MD*

- Discussion

*Julie R. Lange, MD*

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

*Lore Decoster, MD*

7 #8519^--A phase II randomized study of ramucirumab (IMC□1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

*Richard D. Carvajal*

8 #8520-Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma.

*Valerie P Grignol, MD*

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

*Reinhard Dummer*

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

*Roger Mouawad*

- Discussion

*David F. McDermott, MD*

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

*Donald P. Lawrence*

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

*Ahmad A. Tarhini*

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

*Omid Hamid*

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

*Axel Hauschild*

- Discussion

*Henry B. Koon, MD*

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

*Jun Guo, MD, PhD*

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

*Lynn G. Feun*

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

*Grant A. McArthur, PhD*

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

*Naomi B. Haas*

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

*Wen-Jen Hwu*

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

*Alain Patrick Algazi*

- Discussion

*Anna C. Pavlick, MD*

**Session Title:** #7: Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News"

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 11:30 AM - 12:45 PM

- Communication about Cost of Cancer Care  
*Lidia Schapira, MD*
- Communicating the Costs and Benefits of Medical Interventions  
*Deborah Schrag, MD*
- Inside the Patient-Physician Encounter: Communication and Value  
*Anthony Back, MD*

**Session Title:** #14: Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 11:30 AM - 12:45 PM

- WHAT CAN WE LEARN?: The scientific justification for consideration of mandatory research biopsy within some clinical trials. What questions can research biopsies address? Are they safe? What have we learned from such studies? What is at stake if make all correlative science components optional?  
*Eric P. Winer, MD*
- ARE WE ASKING TOO MUCH?: Ethical Concerns over Mandatory Research Biopsy: Concerns over coercion. Need to separate therapeutic trials from correlative studies. Perspectives of a Patient Advocate within a National Cancer Institute Cooperative Group.  
*Michael Katz*
- THE ETHICAL FRAMEWORK: Can we pursue mandatory research biopsy under select circumstances? Ethical arguments for mandatory research biopsy, ways to promote protection of research subjects and pursue important research. A proposed framework for consideration of mandatory research biopsy and clarification of the assumptions underlying different positions on this issue.  
*Jeffrey M. Peppercorn, MD, MPH*

**Session Title:** #47: Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 11:30 AM - 12:45 PM

- Phase III trial results and the impact on standard of care and trial design

*Michael J. Morris, MD*

- Second line treatment after docetaxel

*Kim N. Chi, MD, FRCPC*

- Bone directed therapy for prostate cancer: present standards and potential new options

*Evan Y. Yu, MD*

**Session Title:** #123: The Hospital/Physician Relationship: Tensions Arising

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 11:30 AM - 12:45 PM

- Where We Have Been, Where We Are: The Life of a Practice and the Pros and Cons of Intersecting with the Hospital

*Barbara L. McAneny, MD*

- Options for Practice and for Hospitals: How to Balance For-profit and Nonprofit Entities?

*Michael L. Blau, JD*

- Why We Must Cooperate: An Integrated Health Care Delivery Model Is Important - Cost and Quality and Survival

*Lowell E. Schnipper, MD*

- The Future Drives Us Together: New Payment Schemes - Where Episode of Care Leaves Oncology? Can You Survive Outside of the Institution?

*Hoangmai Pham, MD, MPH*

**Session Title:** #133: Management of Less Common Head and Neck Cancers

**Session Type:** Clinical Problems in Oncology Session

- Salivary gland cancer  
*David J. Adelstein, MD*
  - Nasopharyngeal carcinoma  
*Quynh-thu Le, MD*
  - Cutaneous melanoma of the head and neck  
*Carol Rossier Bradford, MD*
- 

**Session Title:** #247: Genitourinary (Prostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 12:00 PM - 1:00 PM

- Genitourinary (Prostate) Cancer  
*Andrea Lynne Harzstark, MD*
- Genitourinary (Prostate) Cancer  
*Daniel W Lin*

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

*Nicholas Mitsiades, MD, PhD*

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

*Shreya K. Shah*

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

*Aseem Anand*

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

*Eleni Efstathiou*

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

*Tomasz M. Beer, MD, FACP*

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

*Emmanuel S. Antonarakis, MD*

- Discussion: Biomarkers of response in prostate cancer

*Johann Sebastian De Bono, MD, PhD*

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-&Tau; trials in metastatic castration-resistant prostate cancer.

*Celestia S. Higano, MD*

8 #4551-Persistence of immunotherapy survival effects of sipuleucel-&Tau; and relationship to postrandomization docetaxel use in phase III studies.

*Daniel Peter Petrylak*

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel-&Tau;;, an autologous active cellular immunotherapy for the treatment of prostate cancer.

*Frances P Stewart*

- Discussion: Can we predict who will respond to immunotherapy?

*Robert Dreicer, MD*

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

*Paul L. De Souza*

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

*Daniel Keizman*

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

*Mark T. Fleming*

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

*Mark N. Stein*

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

*Mary-Ellen Taplin, MD*

- Discussion: Novel therapies and response predictors for CRPC

*Celestia S. Higano, MD*

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

*Evan Y. Yu, MD*

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

*Karynsa Cetin*

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

*Shireen Marzouk*

- Discussion: The impact of ADT on bone and brain

*Matthew Raymond Smith, MD, PhD*

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*David G Bostwick*

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*Otis W. Brawley*

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

*Douglas Reding*

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

*Silke Gillissen*

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

*E. David Crawford*

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

*Joel B. Nelson, MD*

---

**Session Title:** #253: Lung Cancer - Metastatic

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 12:00 PM - 1:00 PM

- Lung Cancer - Metastatic

*Taofeek Kunle Owonikoko, MD*

- Lung Cancer - Metastatic

*Shirish M. Gadgeel, MD*

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

*Andreas Claudius Hoffmann*

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

*David R. Gandara*

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

*Rafael Rosell*

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

*Bruce E. Johnson, MD*

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

*Lecia Sequist, MD*

- Discussion: Biomarkers

*Michael J. Kelley, MD*

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

*Rabab Mohamed Gaafar*

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

*Lampros Vamvakas*

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

*Geoffrey Raymond Oxnard*

10 #7521-A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

*Chih-Hsin Yang*

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

*Suresh S. Ramalingam, MD*

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

*Michael J. Boyer*

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

*Natasha B. Leigh*

- Discussion: New approaches in EGFR targeted therapy

*Karen L. Reckamp, MD, MS*

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

*Jin Soo Lee*

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

*Fairooz F. Kabbinavar*

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

*Baohui Han*

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

*George R Blumenschein, Jr, MD*

- Discussion: Anti-angiogenic agents

*Silvia Novello, MD, PhD*

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

*Hiroshige Yoshioka*

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

*Thomas James Lynch*

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

*Primo Lara, MD*

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) &plusmn; bevacizumab (B) &plusmn; dulanermin (D) in non-small cell lung cancer (NSCLC).

*Fiona Hellen Blackhall*

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

*Christos Stelios Karapetis*

- Discussion: New agents

*Suresh S. Ramalingam, MD*

---

**Session Title:** #166: Sarcoma

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 1:00 PM - 4:00 PM

- Sarcoma

*Richard Riedel, MD*

- Sarcoma

*Mark Agulnik, MD*

- #10000-Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

*Alberto S. Pappo, MD*

- #10001-AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.

*William D. Tap, MD*

- #10002-Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.

*Richard Hong Hui Quek*

- Discussion

*Jeffrey Toretsky, MD*

- #10003-Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS).

*Alessandro Gronchi*

- #10004-A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

*Claire F. Verschraegen, MD*

- #10005-Identification of selective inhibitors of dedifferentiated liposarcoma cells by high-throughput screening (HTS).

*Christina Vadala Angeles, MD*

- Discussion

*Andrew J. Wagner, MD, PhD*

- #10006-Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

*Christopher Corless*

- #10007-In vitro activity of novel KIT/PDGFRα switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors.

*Michael C. Heinrich, MD*

- #10008-Succinate dehydrogenase in *KIT/PDGFRα* wild-type gastrointestinal stromal tumors.

*Katherine A. Janeway*

- Discussion

*Robert D Marsh, MD*

---

**Session Title:** #201: Genitourinary Cancer

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 1:00 PM - 5:00 PM

1A #4566-The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience.

*Siobhan P Lynch*

1B #4567-Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer.

*Tanya B. Dorff*

1C #4568-Concentration-depth profiles of mitomycin-C in the human bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration.

*Gioia Leprini*

1D #4569-Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028.

*Derek Raghavan, MD, PhD*

1E #4570-The impact of a bladder cancer diagnosis on smoking behavior: An opportunity to improve care.

*Jeffrey C Bassett*

1F #4571-Evaluation of African American ethnicity and socioeconomic status as prognostic factors for overall survival in bladder cancer.

*Fen Jiang*

1G #4572-Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder.

*Hussein Mustafa Khaled*

1H #4573-Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC).

*Matt D. Galsky*

2A #4574-Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05).

*Susanne Krege*

2B #4575-Validation of a trimodalitiy treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome.

*Frens Steffen Krause*

2C #4576-Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

*Guru Sonpavde*

2D #4577-Comparison of HER2 amplification in primary tumors and lymph node metastases of urinary bladder cancer.

*Achim Fleischmann*

2E #4578-Influence of age and socioeconomic status (SES) on testicular cancer (TC) specific mortality: A population-based study of 27,948 patients.

*Sophie D. Fossa, MD*

2F #4579-Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.

*Andreas Burchert*

2G #4580-Management of testicular neoplasms in France and compliance with national guidelines.

*Stephane Culine*

2H #4581-2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial.

*Mark Bachner*

3A #4582-Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study.

*Christian K. Kollmannsberger, MD*

3B #4583-Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT).

*Darren Richard Feldman*

3C #4584-Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts) with metastatic germ cell tumors (mGCT).

*Mikhail Fedyanin*

3D #4585-Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel.

*Karin Oechsle*

3E #4586-Residual tumor resection in patients with germ cell tumors (GCT): Use of IGCCCG risk group and tumor volume to predict additional vascular procedures.

*Christian Winter*

3F #4587-Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study.

*Alexey Tryakin*

3G #4588-A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

*Asim Amin*

3H #4589-Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).

*Giuseppe Procopio*

4A #4590-A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).

*Jonathan E. Rosenberg, MD*

4B #4591-Interleukin-2 (IL-2) based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008.

*Frede Donskov*

4C #4592-Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone.

*Pierre Karakiewicz*

4D #4593-Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma.

*Frederic Pouliot*

4E #4594-TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN- $\alpha$ );).

*Sujata Patil*

4F #4595-Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.

*Pasi Korhonen*

4G #4596-Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit&ndash;risk conjoint study.

*A. Brett Hauber*

4H #4597-Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN- $\alpha$ );): Analysis of the pivotal randomized trial.

*Julia Wilkerson*

5A #4598-Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts).

*Derek Way-Jun Shek*

5B #4599-Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

*Pankaj Bhargava*

5C #4600-Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group.

*Laurence Albiges*

5D #4601-A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib.

*Nasreen A. Ilias-Khan*

5E #4602-Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials.

*Fabio Augusto Barros Schutz*

5F #4603-The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

*Thomas Powles*

5G #4604-Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study.

*Elizabeth Rosenberg Plimack*

5H #4605-Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies.

*Martin Gore*

6A #4606-Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma.

*Zita Dubauskas Lim*

6B #4607-Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue.

*Axel Bex*

6C #4608-Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).

*Susanne Osanto, MD, PhD*

6D #4609-Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.

*Georges R Azzi*

6E #4610-Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC).

*Ana M. Molina*

6F #4611-An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients.

*Roman Casciano*

6G #4612-Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

*Gerald Hans Mickisch*

6H #4613-Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN).

*Stephen Lane Richey*

7A #4614-Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).

*Thomas E. Hutson*

7B #4615-Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating t-regulatory cells (TREG).

*Rodolfo Passalacqua*

7C #4616-Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis

*Xiao Su*

7D #4617-Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib in renal cell carcinoma (RCC).

*Hisashi Kawazoe*

7E #4618-Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group.

*Thomas Gutsch*

7F #4619-Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy.

*Eric Tartour*

7G #4620-The effect of sunitinib on immune parameters and haemopoietic stem cell markers in patients with untreated clear cell renal cancer.

*Simon Chowdhury*

7H #4621-Fibroblast growth factor pathway in renal cell carcinoma.

*Ilya Tsimafeyeu*

8A #4622-Expression of enhancer of zeste homolog 2 in renal cell carcinoma and relationship to downregulation of micro RNA-101.

*Toshihiko Sakurai*

8B #4623-Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.

*Nicole Marie Agostino*

8C #4624-Renal cell carcinoma in octogenarians: Comprehensive analysis using the SEER database.

*Nicholas J Hellenthal*

8D #4625-Single-fraction radiosurgery for treatment of spinal and cerebral metastases from renal cell carcinoma under systemic tyrosine kinase inhibition.

*Michael D. Staehler*

8E #4626-Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib and therapeutic response: An 18f-MISO PET-CT study.

*Florent Hugonnet*

8F #4627-Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma.

*Manuela Schmidinger*

8G #4628-Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial.

*Sergio Bracarda*

8H #4629-Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.

*Jenny J. Kim*

9A #4630-Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).

*Andrea J. Bullock*

9B #4631-Serum lactate dehydrogenase (LDH) is a predictive biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).

*Andrew J. Armstrong, MD, ScM*

9C #4632-A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.

*Howard Mark Sandler*

9D #4633-Treatment of intermediate- or high-risk prostate cancer by dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B): Early results of a prospective comparative trial.

*Benjamin Guix*

9E #4634-Phase I/II trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: Toxicity analysis.

*Harvey Quon*

9F #4635-Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy.

*Daniel Costin Danila*

9G #4636-A sensitive exosome-based biosignature for the diagnosis of prostate cancer.

*Christine Kuslich*

9H #4637-Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial

10A #4638-Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer.

*Michael J. Morris, MD*

10B #4639-Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC).

*Mari Nakabayashi, MD, PhD*

10C #4640-Serum-free circulating DNA as a biomarker of prostate cancer diagnosis.

*Edna Gordian*

10D #4641-Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD).

*Victoria J. Sinibaldi*

10F #4643-Effect of tissue ischemia on prostatic androgen levels.

*Michael Christopher Risk*

10G #4644-Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy.

*Martin Hoejgaard, MD*

10H #4645-Performance of expressed prostatic secretion assays in prediction of surgical pathology outcomes in patients undergoing radical prostatectomy.

*Chris M Whelan*

11A #4646-Correlation of epigenetic silencing of *SOCS3* with a subset of prostate cancer with aggressive behavior.

*Francesco Pierconti*

11B #4647-Prostate cancer metastasis, the non-canonical Wnt pathway and the transcription factor PITX2.

*Ian Vela*

11F #4648-PCA3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.

*Koji Okihara*

11G #4649-Neuroendocrine carcinoma in conjunction with Gleason score 8-10 prostate cancer: Clinical implications for patients treated with radiotherapy.

*Daniel J Krauss*

11H #4650-Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer.

*Po Yee Yip*

12A #4651-Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy.

*Michael J. Donovan*

12B #4652-Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer.

*Carsten Henning Ohlmann*

12F #4653-Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial.

*Matthew Raymond Smith, MD, PhD*

12G #4654-Prostate cancer in men under the age of 50: A comparison of race and outcomes.

*Patrick M Parker*

12H #4655-Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare.

*Michael Grabner*

13A #4656-A population based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency.

*Julian Oliver Kim*

13B #4657-A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned.

*James L. Gulley, MD, PhD, FACP*

13C #4658-Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare.

*Eberechukwu Onukwughu*

13D #4659-Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

*William Gray Hocking, MD*

13E #4660-Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CPRC).

*Geoffrey Colin Buckle*

13F #4661-A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes.

*Geoffrey Gibney*

13G #4662-A phase II study of pre-operative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).

*Kim N. Chi, MD, FRCPC*

13H #4663-Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel.

*Vassiliki Tzelepi*

14A #4664-Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

*Donald L. Trump*

14B #4665-Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC).

*Farshid Dayyani*

14C #4666-Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).

*Richard Cathomas*

14D #4667-Phase I trial of fractionated-dose <sup>177</sup>lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (<sup>177</sup>Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

*Scott T. Tagawa*

14E #4668-Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome.

*Yu-Hui Chen*

14F #4669-Phase I, dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).

*Michael Anthony Carducci*

14G #4670-The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study.

*Terence W. Friedlander*

14H #4671-Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

*Charles J. Ryan*

15A #4672-Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC).

*Diletta Bianchini*

15B #4673-Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.

*Neal D. Shore*

15C #4674-HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.

*Robert B. Montgomery*

15D #4675-Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study.

*William Dale, MD, PhD*

15E #4676-Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy.

*Michael K Brawer*

15F #4677-Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.

*Emilio Porfiri*

15G #4678-Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

*Sten Nilsson*

15H #4679-Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal related events in patients with prostate cancer and bone metastases: A comparison across four European countries.

*Marc Botteman*

16A #4680-Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride (alpharadin) in patients with castration resistant prostate cancer (CRPC) metastatic to bone.

*Jorge A. Carrasquillo*

16B #4681-Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

*Igor Latorzeff*

16C #4682-Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).

*Christoph W Reuter*